The estimated Net Worth of Stephen D Okland is at least $736 Mille dollars as of 3 December 2018. Mr. Okland owns over 7,764 units of Vivani Medical Inc stock worth over $97,874 and over the last 8 years he sold EYES stock worth over $22,570. In addition, he makes $615,755 as Chief Commercial Officer at Vivani Medical Inc.
Sign up
Mr. Okland EYES stock SEC Form 4 insiders trading
Stephen has made over 2 trades of the Vivani Medical Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 7,764 units of EYES stock worth $7,997 on 3 December 2018.
The largest trade he's ever made was selling 7,764 units of Vivani Medical Inc stock on 3 December 2018 worth over $7,997. On average, Stephen trades about 2,533 units every 31 days since 2017. As of 3 December 2018 he still owns at least 23,641 units of Vivani Medical Inc stock.
You can see the complete history of Mr. Okland stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Okland biography
Stephen D. Okland Jr. serves as Chief Commercial Officer of the Company. He was appointed Chief Commercial Officer in May 2018 after serving as our Commercial Vice President, U.S. and Canada since March 2016. Prior to that Mr. Okland was President of Sanford Rose Associates – Okland Group, Inc., from June 2015 to March 2016, where he specialized in commercial executive talent acquisition for early stage to mid-cap size companies in the medical device space. Previously, he served from July 2012 to July 2014, as Vice President, Worldwide Marketing and Sales, at Miramar Labs, Inc., a company that develops, manufactures, and distributes medical devices to treat dermatologic medical conditions, where he led all commercialization activities. From September 2008 through June 2012, Mr. Okland served as Vice President, Worldwide Marketing and U.S. Sales at Medivance, Inc. where he directed the turnaround of all commercialization activities resulting in a $250 million acquisition by Bard Medical. He served as Vice President, U.S. Sales and Marketing at Spectranetics, Inc., directing all U.S. sales and marketing operations from February 2006 through August 2008, at the period when the company was named to Fortune’s 100 Fastest Growing Companies three years in a row. Mr. Okland served as Chief Operating Officer of VASCA, a medical device start-up company, directing and managing sales, marketing, R&D and manufacturing operations from May 2003 through January 2006. Prior to 2003, he held positions of increasing responsibility during 12 years at Boston Scientific Corporation and at Johnson & Johnson Medical, Inc., where he began his career. He earned a Bachelor of Science degree from the University of Wisconsin and a Masters of Business Administration from Texas Christian University.
What is the salary of Stephen Okland?
As the Chief Commercial Officer of Vivani Medical Inc, the total compensation of Stephen Okland at Vivani Medical Inc is $615,755. There are 1 executives at Vivani Medical Inc getting paid more, with Jonathan McGuire having the highest compensation of $1,225,100.
How old is Stephen Okland?
Stephen Okland is 55, he's been the Chief Commercial Officer of Vivani Medical Inc since 2018. There are 11 older and 1 younger executives at Vivani Medical Inc. The oldest executive at Vivani Medical Inc is Aaron Mendelsohn, 67, who is the Independent Director.
What's Stephen Okland's mailing address?
Stephen's mailing address filed with the SEC is 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR, CA, 91342.
Insiders trading at Vivani Medical Inc
Over the last 10 years, insiders at Vivani Medical Inc have traded over $9,497,123 worth of Vivani Medical Inc stock and bought 22,269,890 units worth $31,710,900 . The most active insiders traders include Alfred E Mann, Gregg Williams e E. Mann Living Trust Incume.... On average, Vivani Medical Inc executives and independent directors trade stock every 31 days with the average trade being worth of $1,432,564. The most recent stock trade was executed by Gregg Williams on 13 June 2022, trading 3,800 units of EYES stock currently worth $7,600.
What does Vivani Medical Inc do?
Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company's headquarters are in Los Angeles, California.
What does Vivani Medical Inc's logo look like?
Complete history of Mr. Okland stock trades at Vivani Medical Inc
Vivani Medical Inc executives and stock owners
Vivani Medical Inc executives and other stock owners filed with the SEC include:
-
Jonathan McGuire,
Director -
Stephen Okland,
Chief Commercial Officer -
Stephen D. Okland Jr.,
Chief Strategy & Bus. Devel. Officer -
Edward Randolph,
Vice President - Manufacturing -
Scott Dunbar,
Acting Chief Exec. Officer -
Dr. Jessy Dana Dorn Ph.D.,
VP of Clinical & Scientific Affairs -
Edward David Randolph,
VP of Operations -
Edward Jonathon Sedo,
Acting Chief Accounting Officer & Principal Financial Officer -
Aaron Mendelsohn,
Independent Director -
Ted Randolph,
Vice President - Operations -
Matthew Pfeffer,
Acting Chief Executive Officer, Director -
Gregg Williams,
Chairman of the Board -
Lisa M. Wilson,
Founder & Pres of In-Site Communications and Investor Relations for Second Sight -
Gunnar Bjorg,
Founder -
Thomas B Miller,
Chief Financial Officer -
E. Mann Living Trust Incume...,
-
Gregoire Cosendai,
VP of European Operations -
William J Phd Link,
Director -
David Murray Jacques,
VP-Research Development -
John T Blake,
Chief Financial Officer -
William Patrick Ryan,
Chief Operating Officer -
Jessy Dana Dorn,
VP-Clin & Scientific Affairs -
John Anthony Moses,
Commercial VP Americas -
Robert J. Greenberg,
Chief Executive Officer -
Alfred E Mann,
Director -
Anne Marie Juliette Ripley,
VP Regulatory Affairs